AIT Worldwide Logistics debuts new global headquarters in Chicago suburbs
14.8.2023 18:03:00 EEST | Business Wire | Press release
Corporate teammates for supply chain solutions leader AIT Worldwide Logistics recently moved into a new global headquarters at 2 Pierce Place in Itasca, Illinois. Previously, AIT’s shared services teams were based out of multiple Itasca facilities, including 701 Rohlwing Rd., a single-story building and warehouse that had been shared with the company’s Chicago station since 1997.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230814443050/en/
AIT’s new global headquarters occupies multiple floors of the iconic 25-story suburban tower at 2 Pierce Place in Itasca, Illinois. (Photo: Business Wire)
According to AIT’s Chairman and CEO, Vaughn Moore, the move was spurred by the organization’s exponential growth and emergence as a global logistics powerhouse.
“After more than 40 years in business, and immense expansion to more than 110 locations across Asia, Europe and North America, we’re fortifying our roots in the Chicago area,” Moore said. “This modern, highly visible location is a true manifestation of our global brand, and it provides our corporate staff with both the space and resources they need to best support our customers and teammates around the world.”
Moore added that the new location is a major investment in AIT teammates’ on-site work experience.
“Working together in this state-of-the-art office space allows us to be much more collaborative, enabling faster, real-time reactions,” he said. “2 Pierce Place also provides the additional space we need to accommodate the future growth of our shared services teams.”
AIT’s global headquarters occupies multiple floors of the iconic 25-story suburban tower. Standing at 395 feet, it is the second-tallest building in Illinois outside the Chicago city limits. From its modern lobby to the tenant lounge, game room and outdoor patio, 2 Pierce Place offers popular on-site amenities, including a fitness center, walking trail, a full-service deli serving breakfast and lunch, grab-and-go dining options, and on-site catering services.
Team members from accounting, claims, finance, global business systems, global compliance, human resources, imaging, information technology, legal and marketing are stationed on newly remodeled high-rise floors with conveniences including a private game room, coffee bars, sit-stand workstations, and multiple conference rooms equipped with state-of-the-art audio-visual capabilities.
In the coming months, the remaining Chicago area AIT teams in Itasca and Wood Dale (including dedicated food logistics and life sciences locations) are planning to move into a unified multi-service facility in the nearby suburb of Palatine. This new joint office and warehouse space is under construction. Meanwhile, AIT Truckload Solutions will continue to serve customers out of their current location at 55 W. Monroe St. in Chicago.
Conveniently located near the intersection of Interstate 290 and the Elgin-O’Hare Expressway, AIT’s new global headquarters is easily accessible from O’Hare International Airport:
|
AIT Worldwide Logistics |
|
2 Pierce Place, Suite 2100 |
|
Itasca, IL 60143 |
|
Tel: +1 (630) 766-8300 |
Learn more about 2 Pierce Place at twopierceplace.com.
About AIT Worldwide Logistics
AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For more than 40 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, automotive, consumer retail, food, government, healthcare, high-tech, industrial and life sciences. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes door-to-door deliveries via sea, air, ground and rail — on time and on budget. With expert teammates staffing more than 100 worldwide locations in Asia, Europe and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.
Our Mission
At AIT, we vigorously seek opportunities to earn our customers’ trust by delivering exceptional worldwide logistics solutions while passionately valuing our co-workers, partners and communities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814443050/en/
Contact information
Matt Sanders
Public Relations Manager
+1 (630) 766-8300
msanders@aitworldwide.com
AIT Worldwide Logistics, Inc.
Corporate Headquarters
701 N. Rohlwing Road
Itasca, IL 60143
800-669-4AIT (4248)
www.aitworldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom